Hinge Health’s long-anticipated IPO is generating significant buzz as the first major digital health offering since Waystar’s debut in 2024, raising questions about whether the public markets will value Hinge at or near its prior $6.2 billion private valuation. While the company has shown impressive revenue growth to $390.4M in 2024 and improved margins, concerns remain about future growth beyond the saturated self-insured employer market and its ability to expand beyond musculoskeletal (MSK) care into adjacent areas like behavioral health or GI. As a leader in digital MSK, Hinge faces pressure to either build or buy capabilities in new clinical categories to meet employers’ growing demand for consolidated solutions.
Trending
- Cancer risk comparable across advanced IBD therapies in claims analysis (GI & Hepatology News)
- Independent practice on the road to extinction: Why the next generation won’t own the stethoscope, let alone the building (Medical Economics)
- Fecal Burden on CT Weakly Correlates with Bowel Function in Adults and is Poorly Associated with Clinical Symptoms (Digestive Diseases and Sciences)
- Cook Medical issues medical device correction for Hemospray Endoscopic Hemostat (AGA)
- Medicare physician pay reform 2027: Patients First Act and 4 other bills explained (Physicians Practice)
- FDA Advisory Committee Votes In Favor of Approval of GRAIL’s Galleri® Multi-Cancer Early Detection Test (PR Newswire)
- Batteries that safely break down in the GI tract could improve ingestible devices (Medical Xpress)
- Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls (Gastroenterology)
